A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

The Middle and Friends actor Pat Finn’s cause of death has been released after he died on Dec. 22 at the age of 60. The ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...

Pat Finn, beloved actor from 'The Middle,' has tragically passed away due to complications from bladder cancer after battling ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...